Framingham General CVD Risk Calculator

It reproduces the D’Agostino 2008 lipid-based continuous equation for a 10-year population-model estimate of a first broad general cardiovascular disease event in eligible adults aged 30–74 without established cardiovascular disease.

Sources: [1, 2]

The general-CVD endpoint includes coronary death, myocardial infarction, coronary insufficiency, angina, ischemic stroke, hemorrhagic stroke, transient ischemic attack, peripheral artery disease, and heart failure. It is not an ASCVD-only or coronary-only endpoint.

Sources: [1, 2]

The original lipid-based equation was developed for adults aged 30–74 without established cardiovascular disease at baseline and estimates a first event. This page does not extrapolate it to pregnancy, known CVD, or ages outside that range.

Sources: [1, 2]

The equation estimates a first general CVD event in people without established CVD at baseline. Known CVD is a secondary-prevention context, so this calculator does not produce a result when that status is known or uncertain.

Sources: [1, 2]

The original historical equation was published with two coefficient branches. They are model inputs rather than a determination of gender identity; the equation has no validated third or automatically mixed branch, so use the branch specified by the applicable protocol.

Sources: [1]

Both total cholesterol and HDL must use the same selected unit. The calculator divides mmol/L values by 0.02586 to apply the published mg/dL equation; changing units clears both lipid entries so a number is never silently reinterpreted.

Sources: [1]

It selects the original equation’s treated systolic-blood-pressure coefficient rather than the untreated coefficient. It describes the model branch and does not establish a treatment effect or replace clinical assessment.

Sources: [1]

No. Changing treatment, smoking, diabetes, blood pressure, or lipid inputs creates another model scenario. It does not estimate the causal benefit of starting treatment, stopping smoking, changing cholesterol, or changing blood pressure for an individual patient.

Sources: [1]

No. This is a broad historical Framingham general-CVD model. ASCVD and PREVENT models use different endpoints, populations, predictors, calibration, and clinical pathways; their percentages and thresholds are not interchangeable.

Sources: [1, 5, 6]

SCORE2/SCORE2-OP and QRISK3 are current tools designed for different regional populations and guideline pathways. They use different endpoints, calibration and thresholds, so they should not be substituted for this Framingham general-CVD estimate.

Sources: [1, 7, 8]

Observed event rates, care patterns, risk-factor distributions, and measurement practices differ across populations and time. A model can therefore require external validation or recalibration before its absolute percentages are assumed to transfer.

Sources: [3, 4]

No. It is a population-model estimate, not a prescription, diagnostic result, or automatic treatment decision. Use the relevant current guideline, clinical history and professional judgment.

Sources: [5, 6, 8]